FDA grants paediatric disease designation for Mateon's OT101

FDA

23 September 2019 - For treatment of diffuse intrinsic pontine glioma, a difficult to treat form of childhood brain tumour.

Mateon Therapeutics announced today that the US FDA granted rare paediatric disease designation for OT101/Trabedersen for the treatment of diffuse intrinsic pontine glioma as a drug for a “rare paediatric disease.”

OT101, a first-in-class RNA therapeutic, is designed to abrogate the immunosuppressive actions of TGF-beta 2.

Read Mateon Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder